Ipratropium bromide/salbutamol

Ipratropium bromide/salbutamol
Combination of
Ipratropium bromide	Muscarinic antagonist
Salbutamol	Short-acting β2-adrenergic agonist
Clinical data
Pregnancy; category	C;
Legal status	AU: Pharmacist only; UK: POM (Prescription only); US: ℞-only;
Routes of; administration	Inhalation
Identifiers
ATC code	R03AK04 (WHO)
(verify)

The combination preparation ipratropium bromide/salbutamol is a formulation containing ipratropium bromide (an anticholinergic) and salbutamol sulfate (albuterol sulfate, a β₂-adrenergic receptor agonist) used in the management of chronic obstructive pulmonary disease (COPD) and asthma (not an FDA approved usage).^[2] It is marketed by Boehringer Ingelheim as a metered dose inhaler (MDI) and nebuliser under the trade name Combivent. It is also marketed by Dey, L.P. (Napa, California) under the brand name DuoNeb as a nebulizer. In Italy it is known as Breva. The chemical is sold in India by Cipla as duolin. ^[3]

Since Combivent contains a chlorofluorocarbon based propellant, it is being phased out in European Union countries. Chloroflourocarbons (CFC) are attributed to depletion of the ozone layer.

External links

National Asthma Education and Prevention Program Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health. National Heart, Lung, and Blood Institute; 2007 Aug. NIH Publication No. 07-4051.